Bioequivalence studies
It conducts clinical, analytical and statistical 2×2 bioequivalence studies with 24 to 60 participants.
Source: LinkedIn company description · Retrieved November 17, 2026

Debbiom began in 2005 to offer bioequivalence and bioavailability studies to the national market.
It provides scientific and technological services to the pharmaceutical industry, based on international ethics and quality standards. Its stated focus in Mexico is clinical, analytical and pharmacological research studies for evaluating and developing medicines.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company provides services nationally to the international and national pharmaceutical industry.
It conducts clinical, analytical and statistical 2×2 bioequivalence studies with 24 to 60 participants.
Source: LinkedIn company description · Retrieved November 17, 2026
The listed services include development and validation of analytical methods.
Source: LinkedIn company description · Retrieved November 17, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on November 17, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 18, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 5, 2026, September 16, 2026, November 5, 2026 and November 6, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.